Related references
Note: Only part of the references are listed.Exenatide Use in the Management of Metabolic Syndrome: A Retrospective Database Study
Rajat Bhushan et al.
Endocrine Practice (2013)
Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes
J. Rosenstock et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study
Debora Williams-Herman et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Intensive Glucose-Lowering Therapy Reduces Cardiovascular Disease Events in Veterans Affairs Diabetes Trial Participants With Lower Calcified Coronary Atherosclerosis
Peter D. Reaven et al.
DIABETES (2009)
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
Ralph A. DeFronzo
DIABETES (2009)
Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
Michael Nauck et al.
DIABETES CARE (2009)
Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association
Jay S. Skyler et al.
DIABETES CARE (2009)
Randomized Comparison of Pramlintide or Mealtime Insulin Added to Basal Insulin Treatment for Patients With Type 2 Diabetes
Matthew Riddle et al.
DIABETES CARE (2009)
Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
Bernard Zinman et al.
DIABETES CARE (2009)
Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone A double-blind placebo-controlled study
Michael A. Nauck et al.
DIABETES CARE (2009)
The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
Ralph A. DeFronzo et al.
DIABETES CARE (2009)
One-year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients A randomized, controlled trial
Mathijs C. Bunck et al.
DIABETES CARE (2009)
Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects
M. A. Bush et al.
DIABETES OBESITY & METABOLISM (2009)
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
M. Marre et al.
DIABETIC MEDICINE (2009)
Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients
K. Eeg-Olofsson et al.
DIABETOLOGIA (2009)
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
Alan Garber et al.
LANCET (2009)
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse et al.
LANCET (2009)
Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
William Duckworth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2009)
Mitochondrial Dysfunction, Insulin Resistance, and Type 2 Diabetes Mellitus
Muhammad A. Abdul-Ghani et al.
CURRENT DIABETES REPORTS (2008)
Evolving concepts of type 2 diabetes management with oral medications: new approaches to an old disease
Robert R. Henry
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
David C. Klonoff et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes
Itamar Raz et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis
Leonard C. Glass et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Weight Change in Diabetes and Glycemic and Blood Pressure Control
Adrianne C. Feldstein et al.
DIABETES CARE (2008)
Rosiglitazone no longer recommended
[Anonymous]
LANCET (2008)
Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control A randomized, double-blind, placebo-controlled study
Ralph A. DeFronzo et al.
DIABETES CARE (2008)
Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes
R. Scott et al.
DIABETES OBESITY & METABOLISM (2008)
Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2008)
Effectiveness of the novel anti-diabetes medication exenatide in everyday practice: Comparison with clinical trials
Sirisha Donekal et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2008)
Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes
Jessica E. Matthews et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Leptin resistance - A possible interface of inflammation and metabolism in obesity-related cardiovascular disease
Seth S. Martin et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Daniel J. Drucker et al.
LANCET (2008)
Glycemic targets and cardiovascular disease
William T. Cefalu
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Intensive glycemic control in the ACCORD and ADVANCE trials
Robert G. Dluhy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
Anushka Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The effect of obesity and cardiometabolic risk factors on expenditures and productivity in the United States
Patrick W. Sullivan et al.
OBESITY (2008)
Biological specificity of visceral adipose tissue and therapeutic intervention
Sebastio Perrini et al.
ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY (2008)
Emerging Incretin-Based Therapies for Type 2 Diabetes: Incretin Mimetics and DPP-4 Inhibitors
Anthony Stonehouse et al.
CURRENT DIABETES REVIEWS (2008)
Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin
Matthew Riddle et al.
DIABETES CARE (2007)
Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial
Anthony H. Barnett et al.
CLINICAL THERAPEUTICS (2007)
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes
Barry J. Goldstein et al.
DIABETES CARE (2007)
Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes
Dennis Kim et al.
DIABETES CARE (2007)
Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes
Markolf Hanefeld et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes - A randomized trial
Bernard Zinman et al.
ANNALS OF INTERNAL MEDICINE (2007)
A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study
M. A. Nauck et al.
DIABETOLOGIA (2007)
Primary prevention of cardiovascular diseases in people with diabetes mellitus - A scientific statement from the American Heart Association and the American Diabetes Association
John B. Buse et al.
CIRCULATION (2007)
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
John B. Buse et al.
CLINICAL THERAPEUTICS (2007)
Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes
R. Scott et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2007)
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
Pablo Aschner et al.
DIABETES CARE (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
Bernard Charbonnel et al.
DIABETES CARE (2006)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
I. Raz et al.
DIABETOLOGIA (2006)
Management of Type 2 diabetes: the role of incretin mimetics
Anthony H. Stonehouse et al.
EXPERT OPINION ON PHARMACOTHERAPY (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
Julio Rosenstock et al.
CLINICAL THERAPEUTICS (2006)
Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75)
I. M. Stratton et al.
DIABETOLOGIA (2006)
Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus
R. E. Ratner et al.
DIABETES OBESITY & METABOLISM (2006)
Incretin mimetics and dipeptidyl peptidase-IV inhibitors: Potential new therapies for type 2 diabetes mellitus
C Triplitt et al.
PHARMACOTHERAPY (2006)
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses
GA Herman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes - A randomized trial
RJ Heine et al.
ANNALS OF INTERNAL MEDICINE (2005)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
DM Kendall et al.
DIABETES CARE (2005)
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
RA DeFronzo et al.
DIABETES CARE (2005)
Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm
PC Deedwania et al.
AMERICAN JOURNAL OF MEDICINE (2005)
Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients
P Hollander et al.
OBESITY RESEARCH (2004)
Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects
JJ Meier et al.
DIABETES (2004)
Weight management through lifestyle modification for the prevention and management of type 2 diabetes: Rationale and strategies
S Klein et al.
DIABETES CARE (2004)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
JB Buse et al.
DIABETES CARE (2004)
Importance of weight management in Type 2 diabetes: Review with meta-analysis of clinical studies
JW Anderson et al.
JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION (2003)
Synthetic exendin-4 (Exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes
OG Kolterman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes - A 1-year randomized controlled trial
PA Hollander et al.
DIABETES CARE (2003)
Health outcomes of severely obese type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding
JB Dixon et al.
DIABETES CARE (2002)
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
IM Stratton et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
Metabolic consequences of weight loss on glucose metabolism and insulin action in type 2 diabetes
KV Williams et al.
DIABETES OBESITY & METABOLISM (2000)
Share Paper
